Somatin (somatropin) lyophilisate for solution for injections 1.3 mg. (4 IU) vial №1


Manufacturer: Serbia



Children. Growth dysfunction with insufficient secretion of growth hormone (growth hormone deficiency (GHF); Growth dysfunction associated with Shereshevsky-Turner syndrome or chronic renal failure. Growth dysfunction (standard deviation (GVD) of the current growth is less than -2.5 and the standard deviation is genetically due to growth less than –1) in low-born children with growth below the age norm, those born with a weight and / or body length of less than –2 standard deviations that could not reach the age norm of growth (a hundred the standard deviation of the growth rate is less than 0 during the last year) until they reach 4 years of age or more. Dysplasia in Prader – Willi syndrome to improve the growth and structure of the body. The diagnosis of Prader – Willy syndrome should be confirmed by appropriate genetic tests. Adults. Replacement therapy for adults with severe growth hormone deficiency, the occurrence of growth hormone deficiency in adulthood, patients with severe growth hormone deficiency associated with multiple hormonal deficiency following Wie known pathology of the hypothalamus or pituitary gland, as well as patients who have a deficiency of at least one of the pituitary hormones, except for prolactin. Such patients should undergo an appropriate dynamic test to determine the presence or absence of growth hormone deficiency. For patients in whom growth factor deficiency arose as a child (as a result of congenital, genetic, acquired, or idiopathic causes), the possibility of producing growth hormone after the end of longitudinal growth should be re-evaluated. For patients with a high likelihood of persistent GDR, for example, with congenital or secondary GGR due to a hypothalamic-pituitary disease or stroke, an insulin-like growth factor (IRF-I) <2% BSC without treatment with growth hormone for at least 4 weeks should be considered a sufficient basis for diagnosis DGR. For all other patients, an IRF-I analysis and one growth hormone stimulation test are sufficient.